ARS Pharmaceuticals, Inc. SPRY
Set alert
3.38 USD -0.28 -7.65%
At close · Oct 30
3.38 0.00 0.00%
After hours · Oct 30, 4:27 PM ET
3.35 Day range 3.79
3.38 52-week range 13.06
- YTD
- -70.99%
- 1 year
- -60.79%
- Open
- 3.62
- Prev close
- 3.66
- Mkt cap
- 336.13M
- Vol
- 1.76M
- Avg vol
- 1.66M
- EPS
- -2.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.35
- High
- 3.79
- Forward P/E
- -11.01
- Beta
- 0.83
- Short ratio
- 13.70
- Inst. own
- 95.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2026
- 50-d avg
- 8.64
- 200-d avg
- 9.38
- 1y target
- 28.80
6M chart
Events in this range
- May 15, 2026Earnings: -0.61; estimate -0.53; surprise -15.09%
- May 28, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
- Aug 13, 2026Earnings: —; estimate -0.47655; surprise —%
Signals (23)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2026 | 2 days ago |
| MACD: Sell Signal | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Sep 29, 2026 | 1 month ago |
| RSI: Oversold | Sep 25, 2026 | 1 month ago |
| RSI: Oversold | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| RSI: Oversold | Jul 20, 2026 | 3 months ago |
| SMA: Bearish | Jun 25, 2026 | 4 months ago |
| SMA: Bearish | Jun 25, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 25, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| SMA: Bearish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 21, 2026 | 5 months ago |
| SMA: Bearish | May 13, 2026 | 5 months ago |
| MACD: Sell Signal | May 13, 2026 | 5 months ago |
| SMA: Bullish | May 1, 2026 | 6 months ago |
Key statistics
- Market cap
- 1.05B
- Enterprise value
- 991.06M
- Trailing P/E
- 0.00
- Forward P/E
- -11.01
- PEG ratio
- 0.00
- Price / sales
- 10.57
- Price / book
- 9.16
- EPS (TTM)
- -2.00
- Beta
- 0.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -200.00%
- Revenue (TTM)
- 98.99M
- Revenue growth
- 184.50%
- Free cash flow
- -98.28M
- Total cash
- 200.97M
- Total debt
- 171.20M
- Return on equity
- -136.40%
- Shares outstanding
- 99.30M
- Short % of float
- 37.04%
- 50-day average
- 8.64
- 200-day average
- 9.38
Analyst view
Consensus: none
Price target (mean) 28.80 +752.1% upside
Now 3.38
- Target (low)
- 25.00
- Target (mean)
- 28.80
- Target (high)
- 32.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2026
Expected Aug 13, 2026. Consensus EPS estimate -0.53.
Financials — quick view
SPRY Revenue — quarterly 33.66M
SPRY Net income — quarterly -62.34M
SPRY EPS — quarterly -0.63
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 13, 2026 | Jun 30, 2026 | -0.47655 | — | — | — |
| May 15, 2026 | Mar 31, 2026 | -0.53 | -0.61 | -0.08 | -15.09% |
| Mar 9, 2026 | Dec 31, 2025 | -0.42 | -0.42 | 0.00 | 0.00% |
| Nov 10, 2025 | Sep 30, 2025 | -0.45 | -0.52 | -0.07 | -15.56% |
| Aug 13, 2025 | Jun 30, 2025 | -0.41 | -0.46 | -0.05 | -12.20% |
| May 14, 2025 | Mar 31, 2025 | -0.35 | -0.35 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 28, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Sep 4, 2025 | Roth Capital | init | — | Buy |
| Mar 7, 2025 | Scotiabank | init | — | Sector Outperform |
| Jan 14, 2025 | Raymond James | main | Strong Buy | Strong Buy |
| Jan 13, 2025 | Leerink Partners | main | Outperform | Outperform |
| Oct 8, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ars-pharma.com
News
- ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- ARS Pharma to Report Third Quarter 2026 Financial Results
- 12 Health Care Stocks Moving In Monday's After-Market Session
- SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
- SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
- SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
- SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
- ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
- ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
- SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Your note
Sign in to keep a note on SPRY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FITZPATRICK ALEXANDER A. | Officer | Sale | Jun 11, 2026 | 90,910 |
| FLYNN JAMES E | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 26, 2025 | 0 |
| KARAS ERIC | Officer | Sale | Jun 11, 2026 | 12,176 |
| LOWENTHAL RICHARD E | Chief Executive Officer | Sale | Aug 20, 2025 | 0 |
| ORBIMED ADVISORS, L.L.C. | Unknown | Sale | Aug 25, 2024 | 0 |
| SCOTT KATHLEEN D | Chief Financial Officer | Sale | Aug 20, 2025 | 18,292 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 10.94% | 10,860,977 | 114.47M | Mar 30, 2026 |
| Orbimed Advisors LLC. | 8.35% | 8,288,510 | 87.36M | Mar 30, 2026 |
| Rubric Capital Management LP | 8.06% | 8,000,000 | 84.32M | Mar 30, 2026 |
| Deerfield Management Company, L.P | 7.56% | 7,503,812 | 79.09M | Mar 30, 2026 |
| Millennium Management Llc | 6.02% | 5,982,919 | 63.06M | Mar 30, 2026 |
| Blackrock Inc. | 5.05% | 5,012,254 | 52.83M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.44% | 2,418,584 | 25.49M | May 30, 2026 |
| abrdn Healthcare Opportunities Fund | 1.80% | 1,783,628 | 18.80M | Mar 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.76% | 1,749,763 | 18.44M | Mar 30, 2026 |
| abrdn Healthcare Investors | 1.56% | 1,548,014 | 16.32M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.40% | 1,393,126 | 14.68M | Apr 29, 2026 |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 1.08% | 1,074,609 | 11.33M | Mar 30, 2026 |